Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated t cells in recurrent ovarian cancer

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Kandalaft, Lana E ^a   Powell, Daniel J ^a   Chiang, Cheryl L ^a   Tanyi, Janos ^a   Kim, Sarah ^a   Bosch, Marnix ^b   Montone, Kathy ^a   Mick, Rosemarie ^a   Levine, Bruce L ^a   Torigian, Drew A ^a   June, Carl H ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Northwest Biotherapeutics   (United States)

Author keywords

Adoptive T cell transfer; Autologous immunotherapy; DC vaccines

Indexed keywords

BEVACIZUMAB; CD28 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPERTENSION; IMMUNOPROPHYLAXIS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFER; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 84874625308     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22664     Document Type: Article

References (28)

1. Coukos G, Conejo-Garcia JR, Roden RB, Wu TC. Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 2005; 5:1193-210; PMID:16120050; http://dx.doi.org/10.1517/14712598.5.9.1193.
2. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517-27; PMID:12684428.
3. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177.
4. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102.
5. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006; 15:1014-20; PMID:16702385; http://dx.doi.org/10.1158/1055-9965.EPI-05-0334.
6. Hellström I, Goodman G, Pullman J, Yang Y, Hellström KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001; 61:2420-3; PMID:11289108.
7. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:12837-42; PMID:17652518; http://dx.doi.org/10.1073/pnas.0703342104.
8. Vonderheide RH. Telomerase as a universal tumorassociated antigen for cancer immunotherapy. Oncogene 2002; 21:674-9; PMID:11850795; http://dx.doi.org/10.1038/sj.onc.1205074.
9. Luby TM, Cole G, Baker L, Kornher JS, Ramstedt U, Hedley ML. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin Immunol 2004; 112:45-53; PMID:15207781; http://dx.doi.org/10.1016/j.clim.2004.04.002.
10. Neller MA, López JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008; 20:286-95; PMID:18951039; http://dx.doi.org/10.1016/j.smim.2008.09.006.
11. Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 1998; 10:443-8; PMID:9826577; http://dx.doi.org/10.1006/smim.1998.0147.
12. Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr Opin Immunol 1998; 10:444-9; PMID:9722921; http://dx.doi.org/10.1016/S0952-7915(98)80119-2.
13. Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, et al. Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med 2011; 9:198; PMID:22082029; http://dx.doi.org/10.1186/1479-5876-9-198.
14. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093.
15. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14:28-36; PMID:18157142; http://dx.doi.org/10.1038/nm1699.
16. Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009; 15:4521-8; PMID:19567593; http://dx.doi.org/10.1158/1078-0432.CCR-08-0543.
17. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immunebased mechanism. Clin Cancer Res 2007; 13:3951-9; PMID:17606729; http://dx.doi.org/10.1158/1078-0432.CCR-07-0374.
18. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009; 106:3360-5; PMID:19211796; http://dx.doi.org/10.1073/pnas.0813101106.
19. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor. Mol Ther 2012; 20:633-43; PMID:22127019.
20. Audia S, Nicolas A, Cathelin D, Larmonier N, Ferrand C, Foucher P, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007; 150:523-30; PMID:17956583; http://dx.doi. org/10.1111/j.1365-2249.2007.03521.x.
21. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002; 169:3581-8; PMID:12244148.
22. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153.
23. Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011; 187:6130-42; PMID:22048768; http://dx.doi.org/10.4049/jimmunol.1102209.
24. Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010; 33:211-8; PMID:20139774; http://dx.doi. org/10.1097/CJI.0b013e3181bb499f.
25. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8; PMID:16960692; http://dx.doi. org/10.1007/s00262-006-0225-8.
26. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factorsecreting breast tumor vaccine: a chemotherapy doseranging factorial study of safety and immune activation. J Clin Oncol 2009; 27:5911-8; PMID:19805669; http://dx.doi.org/10.1200/JCO.2009.23.3494.
27. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012; 61:629-41; PMID:22021066; http://dx.doi.org/10.1007/s00262-011-1081-8.
28. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11:5515-25; PMID:16061868; http://dx.doi.org/10.1158/1078-0432.CCR-05-0464.